evipedia.ai
← Back

Haberlea rhodopensis Leaf Extract for Skin Rejuvenation

Evidence Review created on 11/10/2026 using AI4L / Opus 5.5

Also known as: Haberlea Extract, Haberlea rhodopensis Extract, Orpheus Flower Extract, Resurrection Plant Extract, Myconoside-Rich Extract, Chronoglow, InnovaBioTech Haberlea

Motivation

Haberlea rhodopensis leaf extract comes from the leaves of the Orpheus flower, a small Balkan “resurrection plant” that can dry out almost completely and then revive within hours of rain. The extract is of interest because the compounds the plant builds to survive drying and strong light might also help human skin cope with sunlight and everyday wear, which drive visible skin aging.

The leaves have a long history in Bulgarian folk use as a restorative tea. Over the past fifteen years, large cosmetic ingredient makers have turned the extract into branded skin-care ingredients, and it now appears in creams, serums, primers and sunscreens. Interest grew after a small company-run study in volunteers measured skin firmness and radiance, and after cell studies in Bulgarian and Greek laboratories examined how its main plant compounds act on skin cells.

This review examines what is known about the extract for skin rejuvenation: its proposed actions on skin firmness, radiance and sun damage, the strength and independence of the evidence, the risks of applying it, and how products are made and sourced, for adults who pursue a demanding, longevity-oriented skin-care routine.

Benefits - Risks - Protocol - Conclusion

Overview papers that discuss Haberlea rhodopensis extract and its skin-relevant compounds in depth.

Only four items are listed: no further blog posts, podcasts, lectures or overview articles discuss this extract in depth. None of the priority experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, Lifespan.io) has published content on Haberlea rhodopensis; web searches and their site searches returned no matching content.

Grokipedia

Haberlea

Covers the plant’s botany, conservation status and folk use, with a cosmetic-use section summarizing the 2012 industry study and naming commercial ingredients; it repeats supplier figures without weighing them.

Examine

No Examine article on Haberlea rhodopensis leaf extract exists.

ConsumerLab

No ConsumerLab article on Haberlea rhodopensis leaf extract exists.

Systematic Reviews

No systematic reviews or meta-analyses for Haberlea rhodopensis Leaf Extract were found on PubMed as of November 10, 2026.

Neither the claimed skin benefit nor the principal risk (skin irritation or allergy) is represented by a systematic review or meta-analysis.

Mechanism of Action

Haberlea rhodopensis survives near-total drying by accumulating protective sugars and phenolic compounds; the most abundant is myconoside, a caffeoyl phenylethanoid glycoside (a sugar-bound plant antioxidant), alongside the related calceolarioside E. The proposed skin actions follow from that chemistry:

  • Antioxidant defense: Myconoside and calceolarioside E raised levels of NRF2 in neutrophils (a type of white blood cell) (Amirova 2021). In UV-exposed HaCaT keratinocytes (a standard human skin-cell line), the extract and both compounds reduced ROS (reactive oxygen species, unstable oxygen molecules that damage cells) (Stoykova 2024).
  • Dermal (deeper skin layer) matrix signaling: In UV-exposed keratinocytes, myconoside and calceolarioside E raised expression of COL1A1 (the gene for type I collagen) and PPARGC1A (the gene for PGC-1α, a regulator of mitochondrial energy production) (Stoykova 2024); only myconoside raised TGFB1 (the gene for TGF-β, a growth signal that drives collagen production) (Stoykova 2024).

Competing considerations:

  • Skin penetration: Compounds above about 500 daltons (a unit of molecular mass) cross intact skin poorly (Bos 2000); myconoside is a large multi-sugar molecule, and its penetration has never been measured.
  • Dose window: Myconoside at 20 μg/mL reduced viability of lung cancer cells (Kostadinova 2022), so concentration matters.

As a botanical extract, its pharmacology is uncharacterized: no human data exist on the half-life, selectivity, tissue distribution or metabolism of myconoside or calceolarioside E.

Historical Context & Evolution

According to a review, use of Haberlea rhodopensis dates back to the Thracian and Roman periods (Georgiev 2020); Bulgarians call it the Orpheus flower and use its leaves for teas and extracts with detoxifying, tonic, restorative and rejuvenating effects, and traditionally for wound healing and cattle diseases (Georgiev 2020). Its original intended use was therefore oral folk medicine, not skin care.

Scientific attention began with its resurrection physiology. According to the same review, Bulgarian groups then tested a 70% ethanolic leaf extract as a radioprotective agent (protecting against radiation damage) (Georgiev 2020); a review explains the effect by preservation of lymphocytes (a type of white blood cell) and other blood cells under gamma radiation via stimulation of antioxidant enzymes (Georgiev 2020). That antioxidant profile and revival ability made it a skin-care candidate.

Cosmetic use was driven by industry: a 2012 paper combined fibroblast, skin-biopsy and volunteer data (Dell’Acqua 2012); its authors worked for Induchem AG. Givaudan acquired Induchem in 2015 (Givaudan acquisition release) and launched its Chronoglow ingredient from the plant in 2021 (Givaudan press release). Because the species is protected in Bulgaria under Annex 3 of the Biodiversity Act, as stated by the Ministry of Environment and Water (MOEW press release), producers moved to lab-grown in vitro cultures.

What changed since 2012 is the depth of cell data, not the human data: academic groups added NRF2 and keratinocyte findings, while no independent group has repeated a human trial. The 2012 findings therefore remain neither confirmed nor contradicted in people.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the only human outcome data come from one 20-person controlled trial run by a single industry research group.

Medium 🟩 🟩

Skin Elasticity

When tested in 20 human volunteers at 3% in a cream against a placebo, Haberlea extract increased skin elasticity after 15 days, with the effect sustained after 30 and 60 days (Dell’Acqua 2012). The authors worked for Induchem AG, which developed the extract, and the abstract does not report participant age, sex, randomization, blinding or the measuring device. Givaudan reports elasticity gains for Chronoglow of up to 8.9% at 2 weeks (Givaudan press release) and 15.3% at 2 months (Givaudan press release), without peer review.

Magnitude: Elasticity increase 3 times that of placebo after 15 days (P < 0.0002; P is the probability of a difference this large arising by chance) (Dell’Acqua 2012); the abstract gives no between-group difference in absolute units and no 95% CI (confidence interval, the range likely to contain the true effect).

Skin Radiance

In the same 20-volunteer placebo-controlled trial, the 3% Haberlea cream increased skin radiance after 15 days, with the effect sustained after 30 and 60 days (Dell’Acqua 2012). Radiance describes how much light the skin reflects evenly; the abstract does not name the method. Givaudan reports radiance gains for Chronoglow of up to 6.1% at 2 weeks (Givaudan press release) and 12.5% at 2 months (Givaudan press release), without peer review.

Magnitude: Radiance increase 4 times that of placebo after 15 days (P < 0.05) (Dell’Acqua 2012); the abstract gives no between-group difference in absolute units and no 95% CI.

Low 🟩

No benefit is graded Low: beyond the one controlled trial, there are no uncontrolled human series, case reports or indirect human data on this extract.

Speculative 🟨

Protection Against UV-Induced Oxidation

At 3% in human skin biopsies, the extract protected against UV-induced dermis (deeper skin layer) oxidation (Dell’Acqua 2012). It also reduced ROS in UV-exposed keratinocytes (Stoykova 2024). Basis: tissue and cell data only.

Dermal Matrix Gene Expression

In peroxide-stressed human dermal fibroblasts, the extract increased collagen VI, collagen XVI and elastin mRNA (gene messages for protein production) (Dell’Acqua 2012). Gene messages are not measured collagen or wrinkles. Basis: cell data only.

Keratinocyte Wound Closure ⭕️ Not Central to Skin Rejuvenation

At 20 μg/mL, the ethanolic extract enhanced scratch-wound closure in keratinocyte monolayers (single-layer cell cultures), reaching complete closure by 36 hours (Ermogenous 2026). This bears on skin repair, not visible aging. Basis: cell data only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No gene variant has been studied for response to this extract; variants in the NRF2 pathway are a plausible but untested modifier.
  • Baseline skin elasticity: Skin with lower starting elasticity, such as sun-damaged skin, likely has more room to improve; the 2012 abstract reports no baseline values (Dell’Acqua 2012), so this is inference.
  • Sex: No sex-based difference has been studied; the 2012 abstract does not report the sex of participants (Dell’Acqua 2012).
  • Pre-existing conditions: Heavy sun damage may offer more room for antioxidant-related gains; barrier disorders such as eczema are untested and may change how much extract enters the skin.
  • Age: Older skin loses collagen and elasticity faster, which may make gains easier to detect; no age-stratified data exist, including for adults in their 70s and beyond.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no trial from any research group has published adverse-event data for the extract.

Medium 🟥 🟥

No risk reaches Medium: neither a single trial nor a controlled observational study reports adverse-event rates for the extract.

Low 🟥

No risk reaches Low: no case reports, case series or indirect human data describe harm from Haberlea rhodopensis extract.

Speculative 🟨

Contact Irritation or Allergy

Botanical extracts can cause irritation or allergic contact dermatitis (a delayed immune rash at the contact site). No patch-test study exists; the 2012 trial abstract reports no tolerability data (Dell’Acqua 2012). Basis: general botanical experience.

Concentration-Dependent Cell Toxicity ⚠️ Conflicted

Myconoside at 20 μg/mL harmed lung cancer cells (Kostadinova 2022); extract at 25–100 μg/mL spared normal cells (Vasileva 2024) but harmed keratinocytes from 160 μg/mL (Ermogenous 2026). Net reading from cell data: toxicity is concentration-dependent.

Risk-Modifying Factors

  • Genetic polymorphisms: No variant is known to change risk from this extract; people with atopic tendencies (inherited tendency to eczema, hay fever or asthma), including filaggrin (a skin-barrier protein) gene variants, generally react more to topical products.
  • Baseline biomarkers: No blood or skin biomarker predicts reactions; a prior positive patch test to botanical mixes signals higher allergy risk.
  • Sex: No sex-based difference in reactions has been studied for this extract.
  • Pre-existing conditions: Eczema, rosacea (a chronic facial redness condition) and freshly treated skin have weaker barriers; a review reports that extracts disrupted keratinocyte tight junctions (cell-to-cell seals) in vitro (Djilianov 2024).
  • Age: Older skin is thinner and drier and often reacts more to new topical products; no age-specific safety data exist.

Key Interactions & Contraindications

Documented interactions:

  • None identified

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Prescription topical retinoids (vitamin A-derived skin drugs; tretinoin, tazarotene, adapalene): Inferred from shared dermal-matrix signaling; combined use may add collagen-gene effects but also stacks barrier stress, raising irritation. Applying them at different times of day limits this.
  • Over-the-counter exfoliants (glycolic acid, salicylic acid, benzoyl peroxide): Inferred from barrier disruption increasing penetration of extract constituents; consequence is possible stinging or redness. Separate application times and introducing one product at a time reduce this.
  • Oral prescription medicines (warfarin, atorvastatin): Inferred from topical use with unmeasured systemic absorption; no clinically meaningful effect on blood levels is expected. No action beyond usual product introduction.
  • Topical antioxidant supplements and serums (vitamin C, vitamin E, ferulic acid): Inferred from additive antioxidant activity; consequence is possible added protection against oxidation, untested. Layering typically follows a patch test of each product.
  • Oral NRF2-activating supplements (sulforaphane, curcumin): Inferred from additive activation of the same antioxidant switch; consequence is an untested additive effect, without known harm.
  • In-office procedures (chemical peels, microneedling, laser resurfacing): Inferred from breached barrier allowing deeper penetration; consequence is possible irritation on treated skin. Use is typically resumed only after the skin has healed.

Populations who should avoid Haberlea rhodopensis Leaf Extract:

  • People with a known allergy to Haberlea rhodopensis or other Gesneriaceae (the African violet family), or to any listed product ingredient: inferred from general contact-allergy principles; no human data.
  • People with broken, eroded or actively inflamed skin at the application site: inferred from in vitro disruption of keratinocyte tight junctions reported in a review (Djilianov 2024); no human data.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Patch test first: The product is applied to the inner forearm twice daily for 7 days before facial use; stopping at any redness, itch or papules (small raised spots) prevents a full-face allergic contact dermatitis.
  • Intact skin only: Use typically waits at least 7 days after peels, microneedling or laser treatment and pauses during eczema or rosacea flares; this limits penetration-related irritation on a weakened barrier.
  • Stop at persistent reaction: Use stops if redness, swelling or itch lasts beyond 48 hours, and a spreading rash warrants a dermatologist’s assessment; this prevents a developing contact allergy from worsening.
  • One new product at a time: The Haberlea product is introduced alone for 2 weeks before other actives are added; this lets any irritation or allergy be traced to its cause and stopped early.
  • Studied strength: Products disclosing about 3% extract match the strength tested in volunteers (Dell’Acqua 2012); this avoids untested high-myconoside exposure linked to cell toxicity.

Therapeutic Protocol

Timing, frequency, cycling and other parameters without a citation reflect common practice.

  • Concentration: 3% Haberlea extract in a cream, the only strength tested in volunteers (Dell’Acqua 2012); commercial products rarely disclose their percentage.
  • Competing approaches: Single-ingredient supplier formulations follow the Induchem-Givaudan data; multi-active serums from Innova BM-supplied cultures follow cell data only; neither replaces established options such as sunscreen or retinoids, which have their own evidence.
  • Popularizers: Induchem AG, later Givaudan, introduced the extract with the 2012 study and the Chronoglow ingredient (Givaudan press release); Bulgarian supplier Innova BM promotes culture-grown extracts (SpecialChem Innova BM news).
  • Frequency and split dosing: Applied once or twice daily to cleansed face and neck; the 2012 abstract does not state frequency (Dell’Acqua 2012), so twice-daily split use is common practice.
  • Time of day: Morning use under sunscreen fits the proposed antioxidant role against daytime UV; evening use suits pairing away from retinoids.
  • Half-life: No human half-life or skin-retention data exist for myconoside or calceolarioside E; effects, if any, presumably require continued application.
  • Duration: Volunteer effects were reported from 15 days through 60 days of use (Dell’Acqua 2012).
  • Genetic polymorphisms: No gene variant is known to change protocol or concentration choice.
  • Sex: No sex-based difference in response or dosing has been reported; the same concentration applies.
  • Age: Older adults, including those over 70, may start with once-daily use given drier, thinner skin; no age-specific dosing data exist.
  • Baseline biomarkers: A baseline elasticity measurement or standardized photograph allows judging response; lower starting elasticity may show more change.
  • Pre-existing conditions: People with eczema or rosacea may begin with once-daily use after a patch test; no condition-specific data exist.

Discontinuation & Cycling

  • Duration of use: Use is ongoing for as long as a benefit is wanted; no study followed users beyond 60 days.
  • Withdrawal effects: No withdrawal effects are known or expected for a topical botanical extract.
  • Tapering: No tapering is needed; the product can be stopped at once.
  • Cycling: No data show that cycling preserves efficacy; continuous use matches the only volunteer trial.
  • Reassessment: Comparing standardized photographs or elasticity readings after 2 months of use shows whether continuing is worthwhile.

Sourcing and Quality

  • Label name: The INCI (International Nomenclature of Cosmetic Ingredients) name is “Haberlea Rhodopensis Leaf Extract”, listed in the EU (European Union) ingredient database as skin conditioning (EU CosIng entry).
  • Wild versus culture-grown: Lab-grown cultures contained 83.77 mg/g myconoside versus 6.51 mg/g in wild plants (Amirova 2021); a stated myconoside content indicates standardization.
  • Conservation: The plant is a protected species under Annex 3 of Bulgaria’s Biodiversity Act (MOEW press release); culture-grown sourcing avoids legal and ecological problems of wild collection.
  • Ingredient suppliers: Givaudan sells Chronoglow (Haberlea rhodopensis leaf extract in glycerin and water) (SpecialChem Chronoglow datasheet); Innova BM sells InnovaBioTech Haberlea (SpecialChem Innova BM news).
  • Finished products: The extract appears in products from brands including Dior, Estée Lauder, Obagi and iS Clinical (INCIDecoder ingredient page); its position in the ingredient list hints at concentration.
  • Third-party testing: No independent laboratory tests Haberlea products; certifications such as COSMOS (an organic and natural cosmetics standard) address sourcing, not efficacy or strength.

Practical Considerations

  • Time to effect: In the only volunteer trial, elasticity and radiance changes were reported after 15 days (Dell’Acqua 2012); slower collagen-related changes, if real, would need months.
  • Common pitfalls: Buying products where the extract is a trace ingredient near the end of the list; expecting retinoid-like wrinkle reduction; assuming the folk tea benefits skin; and treating the extract as sunscreen.
  • Regulatory status: In the US, cosmetic ingredients other than color additives need no FDA (Food and Drug Administration) approval before marketing (FDA cosmetics page); the EU database lists no restriction (EU CosIng entry).
  • Who funds the evidence: No insurer pays for cosmetic skin care, so payer incentives do not shape this literature; the only human trial came from the ingredient’s developer.
  • Cost and access: The extract is widely available in mid-priced and luxury skin care; it is neither exceptionally expensive nor hard to obtain.

Interaction with Foundational Habits

  • Sleep: None expected; a topical extract has no known effect on sleep. Evening application is practical when mornings carry sunscreen and other actives.
  • Nutrition: Indirect and potentially additive; diets rich in polyphenol-containing vegetables, fruit and olive oil supply other antioxidants. No food needs to be avoided, and the extract depletes no nutrients.
  • Exercise: None expected; no effect on training adaptation is plausible from topical use. Applying after post-workout cleansing avoids sweat diluting the product; the extract is not a sunscreen, so outdoor training leaves UV exposure unchanged.
  • Stress management: None known; the extract has no studied effect on cortisol. Stress-related skin flares (eczema, rosacea) weaken the skin barrier, when new products are more likely to irritate.

Monitoring Protocol & Defining Success

Before starting, no blood tests are needed for a topical cosmetic extract. Baseline assessment consists of a 7-day forearm patch test, standardized facial photographs under fixed lighting, and, where available, an instrumental elasticity reading at a dermatology or cosmetic clinic, so that later changes can be judged against the individual’s own starting point.

Ongoing monitoring follows a fixed cadence: skin checks daily during the first 2 weeks for redness, itch or papules, then repeat photographs and elasticity readings at 4 weeks and 8 weeks, matching the timepoints of the only volunteer trial, and every 6 months thereafter while use continues. Measurements are taken at the same time of day, on the same facial site, after the same rest period indoors, because humidity and temperature shift skin readings.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Skin elasticity (suction cutometry) No established target; track change from own baseline Expected to change Measured in the 2012 volunteer trial; cutometry gauges skin rebound after gentle suction; same site, time and room conditions
Skin radiance (standardized photography or colorimetry) No established target; track change from own baseline Expected to change Measured in the 2012 volunteer trial; colorimetry measures skin color and brightness with a handheld meter; fixed lighting, camera distance and no makeup
Patch-test site reaction No established target; track any redness, swelling or papules Safety check: a reaction stops use Read daily for 7 days; delayed reactions can appear after 48–96 hours

Qualitative markers:

  • Perceived skin firmness and springiness
  • Evenness and radiance of skin tone in daylight
  • Comfort: absence of stinging, tightness or itch
  • Makeup sitting more evenly as a sign of smoother texture

Emerging Research

  • Ongoing trials: ClinicalTrials.gov lists no registered study of Haberlea rhodopensis extract, myconoside or resurrection-plant extracts (search 11/10/2026), so no ongoing human trial can change the current picture.
  • Calceolarioside E as active: Calceolarioside E activated NRF2 in UV-stimulated keratinocytes (Stoykova 2024); a trial of a calceolarioside-rich extract could strengthen the case if it reproduces sun-damage protection in people.
  • Extracellular vesicles: Culture extracts enriched with extracellular vesicles (tiny cell-released particles) upregulated collagen-related genes in human dermal fibroblasts (Georgieva 2025); supplier Innova BM promotes these findings (SpecialChem Innova BM news).
  • Independent replication: No group outside Induchem and Givaudan has run a human trial; an independent elasticity or wrinkle trial could either confirm or weaken the 2012 company findings (Dell’Acqua 2012).
  • Penetration studies: Measuring whether myconoside reaches the dermis could weaken the case, given that compounds above about 500 daltons cross intact skin poorly (Bos 2000).
  • Safety window: Myconoside cytotoxicity (toxicity to cells) at higher concentrations (Kostadinova 2022) calls for patch-test and repeat-application safety studies in people, which could either reassure or limit use.

Conclusion

Haberlea rhodopensis leaf extract is a skin-care ingredient made from a Balkan plant that can dry out completely and revive. Its main compounds are plant antioxidants that, in laboratory work on skin cells and skin samples, protect against damage from sunlight and switch on genes involved in collagen and the cell’s own defenses.

For people who build a demanding skin-care routine around firmness and radiance, the human evidence is thin. One small, short, placebo-controlled study in volunteers reported better skin elasticity and radiance, but it was run and published by the company that developed the ingredient, and only its summary is openly available. No independent group has repeated it, and claims for sun protection, collagen building and wound repair rest on cell and tissue experiments alone.

The risk side looks small but is largely unmeasured. No harms have been reported in people, yet no study has formally tested skin irritation or allergy, and very high concentrations harmed cells in the laboratory. Product quality varies widely, because many products contain only trace amounts and few disclose their strength; lab-grown sources avoid harvesting a protected wild plant.

Overall, the extract is a plausible, low-risk addition to skin care whose visible benefits rest on a single company-funded study, and whose larger promise remains unconfirmed outside the laboratory.

Top - Benefits - Risks - Protocol